A study to investigate how well BI 764532, at different doses, is tolerated by individuals with DLL3-positive brain tumors
Résumé de l'étude
This study has two parts, Part A (dose escalation) and Part B (dose expansion). This information and consent form is for study participants who are participating in Part A (dose escalation).
Part A of this study aims to determine how well different doses of the investigational drug BI 764532 are tolerated by patients with a brain tumor that is positive for a tumor marker called "DLL3" and has progressed after treatment with standard therapies.
Part A of this study will also evaluate how effective the treatment is based on clinical response (whether it can treat your tumor or prevent it from worsening), as well as based on various biomarkers (characteristics of the body that can be measured) in the blood and tumor tissue. It will also test how quickly or slowly the investigational drug is processed by your body and eliminated.
The collected data were used to determine the recommended dose for Part B (dose expansion) of the study.
In Part B (dose expansion), it will now be further evaluated how well the recommended dose indicated in Part A (dose escalation) is tolerated. As in Part A of this study, Part B will also evaluate the effectiveness of the treatment based on clinical response (whether it can treat your tumor or prevent worsening) as well as based on various biomarkers (body characteristics that can be measured) in the blood and tumor tissue. It will also test how quickly or slowly the investigational drug is processed by your body and eliminated.
(BASEC)
Intervention étudiée
In this study, we want to find out what effect the investigational drug BI 764532 has on patients with tumor tissue confirmed as DLL3-positive.
(BASEC)
Maladie en cours d'investigation
DLL3-positive brain tumors
(BASEC)
• Age: 18 years and older
• Confirmed diagnosis of a brain tumor with evidence of the biomarker Delta-like Protein 3 (DLL3)
• Availability of tumor tissue for analysis of DLL3 protein expression and IDH 1/2 mutation
• Patients with histologically confirmed primary progressive diffuse gliomas for whom standard therapies have failed
• Willingness to undergo all required study procedures
(BASEC)
Critères d'exclusion
• Previous treatment with therapies targeting DLL3
• Patients have been diagnosed with an immunodeficiency or are taking any medications for the treatment of immunodeficiency within 7 days prior to the first dose of BI 764532 (especially systemic corticosteroids at a dose greater than 2.5 mg of dexamethasone per day or something comparable).
• Radiation therapy within the last three months prior to the diagnosis of disease progression, unless the tumor progression is clearly outside the radiation field or is clearly demonstrated by surgery/biopsy.
• Patients with implanted pacemakers, defibrillators, or other implanted metallic or electronic devices, as these would interfere with MRI imaging.
(BASEC)
Lieu de l’étude
Aarau, Lausanne, Zurich
(BASEC)
Sponsor
Boehringer Ingelheim International GmbH
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Patrick Roth
+41 44 255 55 21
patrick.roth@clutterusz.chUniversitätsspital Zürich
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
29.09.2023
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Eine unverblindete, multizentrische Phase-Ib-Dosiseskalationsstudie zu BI 764532, verabreicht als Monotherapie in wiederholten intravenösen Infusionen an Patienten mit DLL3-exprimierenden Gliomen (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible